Reneuron Share Discussion Threads

[brucie5] 10/4/2019 13:19

Thanks Hollywood.

[lauders] 10/4/2019 12:12

Further read-outs from the patients treated in the Phase 1/2 study will be presented at the 6(th) Annual Retinal Cell and Gene Therapy Innovation Summit, taking place in Vancouver, Canada, on 26 April 2019. Information regarding this conference may be found at:



The Company will make a further announcement later this month, when these further read-outs from the study are known.

[hollywood6] 10/4/2019 12:12

The next presentation. It's it a big event. Further results expected before then.

[hollywood6] 10/4/2019 11:55

Expect this to rise to the 26th April

[pdt] 10/4/2019 11:49

Woodford Holding



An article in yesterday's FT quotes Woodford as holding 35% of Reneuron. Doesn't look like he has sold any.

[jensonbensonjohnson] 10/4/2019 11:46

Sit tight Brucie, your bonus will be with you shortly

[brucie5] 10/4/2019 11:36

Am I the only one foolish enough to have bought in yesterday at 2.34? There seem to be two gaps here: the short and the long term. The former is filled by the recent rise; the latter, from 2015, extends to £6, which is also the lower of the broker forecasts. Hopefully the retrace will be shortlived, as the new bottom becomes established at £2. But of course, it remains speculative.

[bigspuds] 10/4/2019 11:24

200 successfully tested

[ken chung] 10/4/2019 10:14

Lemmings and mushrooms only now.

[ken chung] 10/4/2019 10:14

A fine short.

[newtothisgame3] 10/4/2019 09:47

#RENE ReNeuron Group agrees £80mln cell therapy licensing deal for China

[newtothisgame3] 10/4/2019 09:47

#RENE ReNeuron Group agrees £80mln cell therapy licensing deal for China

[masingi] 10/4/2019 09:31

There would be an RNS if Woodford had sold a significant stake.

[14dragon] 10/4/2019 09:10

wigwammer

Woodford must have told him over a pint at the local.

[wigwammer] 10/4/2019 09:00

Good post rayrac. Timw? "timw3...where did you get the view that Woodford had sold down from 30% to 15%?I think he still holds his original stake of 35% within his trusts?Number of ordinary shares % of issued share capitalWoodford Investment Management Limited 35.39%Arthurian Life Sciences SPV GP Ltd, as GP of The Wales Life Sciences Investment Fund LP 9.48%The above information was last updated on Tuesday, 12 March 2019"

[timw3] 10/4/2019 08:23

woodford selling down his holding here.. careful!

[top tips] 10/4/2019 08:06

Rayrac did you manage to get any Toople with you're Rene profits? Its a possible 150x bagger from here.

[buywell2] 10/4/2019 07:51

Exit is stage right

[rayrac] 10/4/2019 07:44

In its retinitis pigmentosa program, Reneuron last week reported the positive effect seen in the first cohort of three patients in the U.S. phase I part of the study of hRPC has been sustained in the first patient cohort in the phase II part of the trial.

All three of the phase I cohort had a rapid and significant improvement in vision and on average were able to read an additional three lines of five letters on EDTRS, a standardized eye chart for measuring measure visual acuity.

[lauders] 10/4/2019 02:41

Congratulations to shareholders who managed to buy in before the recent significant rises. This looks very interesting and I will be watching for any retrace. One would think a retrace will be coming after such a move but you can never tell when great news is behind the rise. Found this piece which peaks my interest in the future here even more:

This makes me appreciate why Fosun was chosen and when Gilead is also mentioned in connection with them it makes me even more interested:

That laid out a route for national approvals for cell therapies. Hunt said Reneuron did some initial scouting and believes that while the regulatory scene is robust, help is needed to navigate it. "That's partly why we chose Fosun, as a responsible and significant player in China, that knows its way round the regulatory framework," said Hunt.

Fosun already has started to make its mark in cell and gene therapy, securing NMPA approval for a phase I trial of Kite Pharma Inc.'s Yescarta (axicabtagene ciloleucel) in the treatment of large B-cell lymphoma, in September last year. (See BioWorld, Sept. 19, 2018.)

The product, designated FKC-876 in China, is being developed by Fosun Kite Biotechnology Ltd., a joint venture set up by Fosun and Kite (now part of Gilead Inc.) in January 2017.

[supernumerary] 09/4/2019 21:10

Sorry, I thought my last sentence made it clear I was firmly in irony mode. I'll try harder in future.

None of which takes away from the conclusion that commercial interests will prevail.

[rotors] 09/4/2019 20:14

s/n (6172)

A little historical squabble? I have worked in China from 1985 and I can tell you that relations are still very frosty.

[supernumerary] 09/4/2019 19:35

There might be a problem with Taiwan, but none whatsoever with Japan. They won't let a little historical squabble stand in the way of making money. And of course, healing the sick.

[rotors] 09/4/2019 19:15

Well, historically there has been friction between China and Japan - would Fosun be happy with this tie up? They are in the driver's seat at the moment.